Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase III drugs for Primary Mediastinal B-Cell Lymphoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Odronextamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Odronextamab overview
Odronextamab (Ordspono) acts as antineoplastic agent. it is formulated as a concentrate solution for the intravenous route of administration. Ordspono is indicated for the treatment of of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy and monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL), after two or more lines of systemic therapy.
Odronextamab is under development for the treatment of relapsed/refractory B- cell non-Hodgkin's lymphomas including relapsed/refractory diffuse large B-cell lymphoma, relapsed/refractory follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, Burkitt Lymphoma, primary mediastinal large B-cell lymphoma and acute lymphoblastic leukemia. The therapeutic candidate is administered intravenously. It is an anti-CD20 and anti-CD3 bi-specific monoclonal antibody. It is developed based on VelociSuite technology. It was under development for B-cell Hodgkin's lymphoma.
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. Regeneron develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick. It also collaborates with strategic partners to develop, manufacture and commercialize its products. The company sells its products to specialty pharmacies and distributors. It operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
For a complete picture of Odronextamab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
